APOL1双等位与单等位变异与西非人群慢性肾脏病
该病例对照研究纳入加纳和尼日利亚8355名参与者,分析APOL1变异与慢性肾脏病(CKD)的关联。携带两个APOL1风险等位基因者CKD的校正比值比为1.25(95%CI 1.11-1.40),局灶节段性肾小球硬化为1.84(95%CI 1.30-2.61);携带一个风险等位基因者CKD的校正比值比为1.18(95%CI 1.04-1.33),局灶节段性肾小球硬化为1.61(95%CI 1.04-2.48)。
要点
- 单等位APOL1变异与CKD风险升高18%、局灶节段性肾小球硬化风险升高61%相关。
- 双等位APOL1变异与CKD风险升高25%、局灶节段性肾小球硬化风险升高84%相关。
- 纳入协变量未改变单等位和双等位APOL1变异与CKD或局灶节段性肾小球硬化的关联。
核心结论
- 本研究中,单等位APOL1变异与CKD风险升高18%及局灶节段性肾小球硬化风险升高61%相关;双等位APOL1变异与CKD风险升高25%及局灶节段性肾小球硬化风险升高84%相关。
研究设计与样本
- 病例对照研究,纳入来自加纳和尼日利亚的参与者,包括CKD 2至5期、活检证实的肾小球疾病或无肾脏疾病者,共8355名(CKD 2至5期4712例、肾小球疾病866例、无肾脏疾病2777例)。
- 采用逻辑回归模型分析CKD与APOL1变异的关联,并控制临床中心、年龄和性别等协变量。
主要发现
- 8355名参与者中,单等位APOL1变异患病率为43.0%,双等位APOL1变异患病率为29.7%。
- 携带两个APOL1风险等位基因者较携带一个或无风险等位基因者CKD的校正比值比为1.25(95%CI 1.11-1.40),局灶节段性肾小球硬化的校正比值比为1.84(95%CI 1.30-2.61)。
- 携带一个APOL1风险等位基因者较无风险等位基因者CKD的校正比值比为1.18(95%CI 1.04-1.33),局灶节段性肾小球硬化的校正比值比为1.61(95%CI 1.04-2.48)。
- 纳入协变量未改变单等位和双等位APOL1变异与CKD或局灶节段性肾小球硬化的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apolipoprotein L1 gene (APOL1) variants are risk factors for chronic kidney disease (CKD) among Black Americans. Data are sparse on the genetic epidemiology of CKD and the clinical association of APOL1 variants with CKD in West Africans, a major group in the Black population. METHODS: We conducted a case-control study involving participants from Ghana and Nigeria who had CKD stages 2 through 5, biopsy-proven glomerular disease, or no kidney disease. We analyzed the association of CKD with APOL1 variants among participants with high-risk genotypes (two APOL1 risk alleles) and those with low-risk genotypes (fewer than two APOL1 risk alleles) by fitting logistic-regression models that controlled for covariates, including clinical site, age, and sex. RESULTS: Among 8355 participants (4712 with CKD stages 2 through 5, 866 with glomerular diseases, and 2777 with no kidney disease), the prevalence of monoallelic APOL1 variants was 43.0% and that of biallelic APOL1 variants was 29.7%. Participants with two APOL1 risk alleles had higher odds of having CKD than those with one risk allele or no risk alleles (adjusted odds ratio, 1.25; 95% confidence interval [CI], 1.11 to 1.40), as well as higher odds of focal segmental glomerulosclerosis (adjusted odds ratio, 1.84; 95% CI, 1.30 to 2.61). Participants with one APOL1 risk allele had higher odds of having CKD than those with no risk alleles (adjusted odds ratio, 1.18; 95% CI, 1.04 to 1.33), as well as higher odds of focal segmental glomerulosclerosis (adjusted odds ratio, 1.61; 95% CI, 1.04 to 2.48). The inclusion of covariates did not modify the association of monoallelic and biallelic APOL1 variants with CKD or focal segmental glomerulosclerosis. CONCLUSIONS: In this study, monoallelic APOL1 variants were associated with 18% higher odds of CKD and 61% higher odds of focal segmental glomerulosclerosis; biallelic APOL1 variants were associated with 25% higher odds of CKD and 84% higher odds of focal segmental glomerulosclerosis. (Funded by the National Human Genome Research Institute and others.).
引用
- Gbadegesin RA, Ulasi I, Ajayi S, et al. APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans. N Engl J Med. 2024. PMID: 39465900. doi:10.1056/NEJMoa2404211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。